Nikolai Alexandrovich Podoltsev MD, PhD

Assistant Professor of Medicine (Hematology); Associate Director of the Hematology/Oncology Fellowship Program

myeloprolipherative neoplasms (MPN); myelodysplastic syndromes (MDS); acute leukemias

nikolai_podoltsevfaculty-clinicsfalsetruefalse

Conditions	Study Title
Smoldering Myeloma	A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Follicular Lymphoma	A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Myelodysplastic Syndromes	Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered in a 72-Hour Continuous IV Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine.